On February 27, 2026, the Department of Health and Human Services announced that roughly 14 of the 19 peptides on the FDA's Category 2 "do not compound" list would be moved back toward Category 1 — and BPC-157 was named among them. Then, on April 15, 2026, BPC-157 was formally removed from the Category 2 bulks list following the withdrawal of its nomination.
That reset drew a lot of attention to peptide legality and sourcing, and it spiked search interest in whether BPC-157 is "legal" now. The honest answer is more nuanced than the headlines.
This is the part most coverage gets wrong. Removal from Category 2 does not automatically grant Category 1 status, and it does not make BPC-157 an approved drug. Each substance still requires individual review by the FDA's Pharmacy Compounding Advisory Committee (PCAC) before it can be reclassified for compounding use. A PCAC meeting to begin evaluating specific peptides is scheduled for July 23–24, 2026.
Even a positive PCAC recommendation doesn't end the process. The FDA would then need to complete a formal Notice of Proposed Rulemaking (NPRM) with a mandatory 60-day public comment period before issuing a Final Rule. Practically, that means official reclassification allowing compounding pharmacies to use bulk BPC-157 is unlikely before late 2026 at the earliest.
As of mid-2026:
In other words: the regulatory door is opening, but it isn't open yet. The "research use only" framing still governs how the compound is sold and how a compliant site like this one writes about it.
The reclassification news reset the supplier landscape and brought new attention — and new sellers — to the space. That makes vendor vetting more important, not less. When the rules are in flux, the constant is verifiable quality: batch-specific third-party Certificates of Analysis (COAs), transparent purity testing, U.S. sourcing, and a real reputation across independent review platforms.
Start with our research overview of the compound and the compared vendor table here: BPC-157: Research Overview & Where to Buy. To understand the single best quality signal, see how to read a Certificate of Analysis on each vendor review.
Is BPC-157 legal in 2026? It's legal to sell and buy as a research material, it's not approved for human use, and it was removed from Category 2 in April 2026 — but full reclassification for compounding is still working its way through PCAC review and FDA rulemaking. Watch the July 2026 PCAC meeting for the next real signal.
Last reviewed June 2026. By Shaun Tucker, B.A. Psychology, author of The Quiet Close. This page is regulatory information, not legal advice.
Join the list for peptide legal updates and honest vendor scores. No spam, ever.